Search Results for: THERAPEUTIC FOCUS Antisense Drug Shown
Articles
THERAPEUTIC FOCUS - Antisense Drug Shown to Significantly Reduce Triglyceride Levels in Patients With Severe Hypertriglyceridemia June 4, 2018
Ioanna Gouni-Berthold, MD, provides results from a clinical study indicating antisense technology can result in significant reductions in triglyceride levels in patients with hypertriglyceridemia.
Biora Therapeutics Announces New Patent Covering its BioJet Liquid Jet Delivery Technology April 8, 2024
Claims cover key jet parameters for liquid jet delivery of a drug to the gastrointestinal tract….
DRUG-ELUTING IMPLANTS - Delivery of RNAi Therapeutics Through Drug-Eluting Implants April 3, 2023
Cyonna Holmes, PhD, Karen Chen, MS, and Brian Wilson, PhD, review how localized therapeutic delivery of these therapies through an implant provides an innovative route of administration for chronic conditions that are difficult to dose adequately.
NeuBase Therapeutics Presents New Preclinical Data for its Myotonic Dystrophy Type 1 Program Demonstrating Splice Rescue, Nuclear Aggregate Resolution & Myotonia Reversal March 14, 2022
NeuBase Therapeutics, Inc. recently announced new preclinical data for its lead development candidate, NT-0231.F, to treat myotonic dystrophy type 1 (DM1). ….
APTAMER TECHNOLOGY - From Postal Codes to GPS: Building Better Drug Conjugates With Aptamers November 30, 2021
David Bunka, PhD, and Emily Robinson, PhD, focus on a new breed of affinity binders that can be used as an alternative to antibody therapeutics and has the potential to reshape the industry, delivering new medicines with improved safety and efficacy profiles and reduced healthcare costs.
MICROFLUIDIC ENCAPSULATION TECHNOLOGY - Achieving Reliable siRNA Drug Delivery for Inflammatory Diseases & Tumor Targeting by Nanoencapsulation March 1, 2021
Olivia Merkel, PhD, and Christoph Zimmermann, PhD student, discuss the benefits of microfluidic encapsulation technology for gene silencing applications in cancer immunology and inflammatory diseases, where siRNA can potentially be used to downregulate genes associated with these pathologies.
OLIGONUCLEOTIDE DELIVERY - Dectin-1 Receptor-Mediated Delivery of Oligonucleotide Drugs Complexed With Schizophyllan Dendritic Cells & Macrophages January 13, 2020
Kenji Arima, PhD, and Akihiko Watanabe, PhD, introduce NapaJen Pharma’s technology with a specific focus on solving some of the current challenges of oligonucleotide therapeutics.
DNA THERAPEUTICS - DNAbilize-ING Antisense March 15, 2018
Peter Nielsen, MBA, explains how his company’s candidates are differentiated from those in development at other companies by the type of modification to the antisense molecule and the method by which it is conveyed to its target cell.
SPECIAL FEATURE - Platform Technologies - Derisking & Transforming Drug Development September 29, 2017
Contributor Cindy H. Dubin, in this second annual report, speaks with several exciting and innovative companies whose platform technologies are transforming drug development.
Akcea & Ionis Report Positive Data From Phase 2 Study Akcea & Ionis Report Positive Data From Phase 2 Study September 26, 2018
Akcea Therapeutics, Inc. and Ionis Pharmaceuticals, Inc. recently announced positive topline results from a Phase 2 clinical study of AKCEA-APO(a)-LRx in patients with established cardiovascular disease (CVD) and elevated levels of lipoprotein(a), or Lp(a).
Bio-Path Holdings Presents Study Results Showing Potential of BP1002 April 10, 2017
Bio-Path Holdings, Inc. recently announced results of preclinical in vitro and in vivo studies supporting the potential of BP1002 in...12/12/2012 December 10, 2012
TNF Inhibitors Lay Groundwork for Next-Generation of Disease-Modifying Anti-Rheumatic Drugs The challenges inherent in the pharmacological management of rheumatic diseases...12/5/2012 November 29, 2012
Curis Announces Several Major Announcements Curis, Inc. recently announced it has licensed from Genentech, a member of the Roche Group,...11/29/2011 November 27, 2011
Biocon Launches Haselmeier's Insulin Pen in India Haselmeier recently announced that Biocon, one of Asia's premier biotechnology companies, has launched...
